Insider Buying: Coya Therapeutics, Inc. (NASDAQ:COYA) CFO Purchases 1,800 Shares of Stock

Coya Therapeutics, Inc. (NASDAQ:COYA) CFO David S. Snyder bought 1,800 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The stock was purchased at an average cost of $7.19 per share, with a total value of $12,942.00. Following the completion of the transaction, the chief financial officer now directly owns 8,800 shares in the company, valued at $63,272. This represents a 25.71 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Coya Therapeutics Stock Performance

Shares of NASDAQ COYA opened at $6.32 on Friday. The stock has a market cap of $105.61 million, a price-to-earnings ratio of -9.72 and a beta of 0.46. Coya Therapeutics, Inc. has a fifty-two week low of $4.75 and a fifty-two week high of $10.69. The firm’s 50-day simple moving average is $7.12 and its 200 day simple moving average is $7.00.

Coya Therapeutics (NASDAQ:COYA) last posted its earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.15. On average, sell-side analysts predict that Coya Therapeutics, Inc. will post -1.15 EPS for the current year.

Hedge Funds Weigh In On Coya Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC raised its holdings in shares of Coya Therapeutics by 3.3% in the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock valued at $918,000 after purchasing an additional 4,485 shares during the last quarter. GHP Investment Advisors Inc. purchased a new position in Coya Therapeutics during the third quarter worth about $169,000. Renaissance Technologies LLC bought a new stake in Coya Therapeutics in the 2nd quarter worth about $101,000. Gilbert & Cook Inc. purchased a new stake in Coya Therapeutics in the 2nd quarter valued at about $61,000. Finally, Vanguard Group Inc. lifted its position in shares of Coya Therapeutics by 772.3% during the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after buying an additional 750,338 shares in the last quarter. 39.75% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Chardan Capital reissued a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Thursday, November 7th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a report on Monday, November 11th.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.